SCHEMBL8902145

SCHEMBL8902145

O=NCCCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3108499 0.96
SCHEMBL10140691 0.77
SCHEMBL28596029 0.74
SCHEMBL765231 0.71
SCHEMBL12040374 0.68
SCHEMBL11150826 0.67
Methane SCHEMBL29133590 0.64
SCHEMBL6050015 0.64
SCHEMBL463669 0.64
SCHEMBL104825 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3978902-B1 MATURITY CLASSIFICATION OF STAINED RETICULOCYTES USING OPTICAL MICROSCOPY SIEMENS HEALTHCARE GMBH (DE) 2023-02-22 EP claimed
US-5593970-A ANTITUMOR AND ANTCARCINOGENIC AGENTS; TRETMENT OF CANCEROUS BONE MARROW BEFORE REGRAFTING BIOCHEM PHARMA INC. (CA) 1997-01-14 US claimed
US-11806337-B2 Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2023-11-07 US disclosed
CN-110818603-B Preparation method of methomyl oxime 湖南海利化工股份有限公司 2022-04-15 CN disclosed
CN-110818603-A Preparation method of methomyl oxime 湖南海利化工股份有限公司 2020-02-21 CN disclosed
CN-109481448-B Application of the Celastrol in induction cancer cell autophagy and its drug combination with Temozolomide 首都医科大学 2019-08-16 CN disclosed
CN-109481448-A Application of the Celastrol in induction cancer cell autophagy and its drug combination with Temozolomide 首都医科大学 2019-03-19 CN disclosed
CN-105177014-B TLR9 synthetic activator 艾德拉药物股份有限公司 2018-04-06 CN disclosed
CN-107530303-A RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS AND USES ADT制药有限责任公司 2018-01-02 CN disclosed
CN-107531615-A Indenyl compound, pharmaceutical composition and medical application thereof ADT制药有限责任公司 2018-01-02 CN disclosed
CN-107466232-A The method for treating or preventing the disease of RAS mediations ADT制药有限责任公司 2017-12-12 CN disclosed
CN-102387817-A Treatment of Brain Derived Neurotrophic Factor (BDNF) related diseases by inhibition of natural antisense transcripts to BDNF OPKO CURNA LLC 2012-03-21 CN disclosed
EP-2407464-A1 BRANCHED COMPOUND, AND ORGANIC THIN FILM AND ORGANIC THIN FILM ELEMENT EACH COMPRISING SAME Sumitomo Chemical Company, Limited (JP) 2012-01-18 EP disclosed
US-20090062255-A1 TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO THALLION PHARMACEUTICALS INC. (CA) 2009-03-05 US disclosed
CN-101267824-A Dosage forms and methods of treatment using a tyrosine kinase inhibitor PFIZER PROD INC (US) 2008-09-17 CN disclosed
CN-1897930-A Compositions and methods for treating contracture ANGIOTECH INT AG (CH) 2007-01-17 CN disclosed
CN-1832743-A dosage form comprising AG013736 AGOURON PHARMA (US) 2006-09-13 CN disclosed
CN-1589151-A Diagnostic or therapeutic somatostatin or bombesin analog linkers and uses thereof UNIV TULANE (US) 2005-03-02 CN disclosed
US-5593970-A ANTITUMOR AND ANTCARCINOGENIC AGENTS; TRETMENT OF CANCEROUS BONE MARROW BEFORE REGRAFTING BIOCHEM PHARMA INC. (CA) 1997-01-14 US disclosed
US-3936576-A POLYISOCYANATE AND AN OXIME AS ADHESIVE THE FIRESTONE TIRE & RUBBER COMPANY (US) 1976-02-03 US disclosed